Table 2.
Tumor and clinical characteristics for the 15 studies in the validation set*
| Study | ER status, No. (%) |
Stage, No. (%) |
Grade†, No. (%) |
||||||||
| Negative | Positive | Missing | I | II | III or IV | Missing | 1 | 2 | 3 | Missing | |
| BBCC | 260 (21.70) | 704 (58.76) | 234 (19.53) | 517 (43.16) | 328 (27.38) | 83 (6.93) | 270 (22.54) | 107 (8.93) | 671 (56.01) | 301 (25.13) | 119 (9.93) |
| CGPS | 313 (16.40) | 1443 (75.59) | 153 (8.01) | 993 (52.02) | 673 (35.25) | 68 (3.56) | 175 (9.17) | 426 (22.32) | 818 (42.85) | 310 (16.24) | 355 (18.60) |
| CNIO-BCS | 32 (15.24) | 93 (44.29) | 85 (40.48) | 109 (51.90) | 66 (31.43) | 2 (0.95) | 33 (15.71) | 47 (22.38) | 61 (29.05) | 43 (20.48) | 59 (28.10) |
| GESBC | 157 (28.65) | 257 (46.90) | 134 (24.45) | 223 (40.69) | 232 (42.34) | 62 (11.31) | 31 (5.66) | 42 (7.66) | 238 (43.43) | 188 (34.31) | 80 (14.60) |
| HEBCS | 402 (18.21) | 1722 (78.02) | 83 (3.76) | 1326 (60.08) | 700 (31.72) | 158 (7.16) | 23 (1.04) | 559 (25.33) | 937 (42.46) | 605 (27.41) | 106 (4.08) |
| KARBAC | 76 (16.00) | 370 (77.89) | 29 (6.11) | 265 (55.79) | 158 (33.26) | 46 (9.68) | 6 (1.26) | 115 (24.12) | 190 (40.00) | 104 (21.89) | 66 (13.89) |
| KBCP | 100 (22.27) | 320 (71.27) | 29 (6.46) | 185 (41.20) | 235 (52.34) | 15 (3.34) | 14 (3.12) | 109 (24.28) | 193 (42.98) | 114 (25.39) | 33 (7.35) |
| kConFab/AOCS | 50 (19.23) | 114 (43.85) | 96 (36.92) | N/A | N/A | N/A | 299 (100) | 49 (18.85) | 87 (33.46) | 69 (26.54) | 55 (21.15) |
| MCBCS | 140 (14.61) | 714 (74.53) | 104 (10.86) | 259 (27.04) | 119 (12.42) | 41 (4.28) | 539 (56.26) | 211 (22.03) | 300 (31.32) | 179 (18.68) | 268 (27.97) |
| MCCS | 149 (22.41) | 449 (67.52) | 67 (10.08) | 333 (50.08) | 119 (17.89) | 9 (1.35) | 204 (30.68) | 140 (21.05) | 273 (41.05) | 193 (29.02) | 59 (8.87) |
| ORIGO | 88 (18.14) | 269 (55.46) | 128 (26.39) | 191 (39.38) | 232 (47.84) | 39 (8.04) | 23 (4.74) | 81 (16.70) | 176 (36.29) | 120 (24.74) | 108 (22.27) |
| PBCS | 524 (29.62) | 1011 (57.15) | 234 (13.23) | N/A | N/A | N/A | 780 (100) | 328 (18.54) | 777 (43.92) | 386 (21.82) | 278 (15.72) |
| SASBAC | 155 (12.63) | 700 (57.05) | 372 (30.32) | 703 (57.29) | 501 (40.83) | 19 (1.55) | 4 (0.33) | 127 (10.35) | 390 (31.78) | 322 (26.24) | 388 (31.62) |
| SBCS | 107 (16.04) | 296 (44.38) | 264 (39.58) | N/A | N/A | N/A | 682 (100) | 125 (18.74) | 287 (43.03) | 207 (31.03) | 48 (7.20) |
| UCIBCS | 165 (15.43) | 606 (56.69) | 298 (27.88) | 730 (68.29) | 261 (24.42) | 46 (4.30) | 32 (2.99) | 124 (11.60) | 353 (33.02) | 285 (26.66) | 307 (28.72) |
| TOTAL | 2718 (19.28) | 9068 (64.33) | 2310 (16.39) | 5834 (41.39) | 3624 (25.71) | 588 (4.17) | 4050 (28.73) | 2590 (18.37) | 5751 (40.80) | 3426 (24.30) | 2329 (16.52) |
BBCC = Bavarian Breast Cancer Cases and Controls; CGPS = Copenhagen Breast Cancer Study and Copenhagen General Population Study; CNIO-BCS = Spanish National Cancer Centre Breast Cancer Study; ER = estrogen receptor; GESBC = Genetic Epidemiology Study of Breast Cancer by Age 50; HEBCS = Helsinki Breast Cancer Study; KARBAC = Karolinska Breast Cancer Study; KBCP = Kuopio Breast Cancer Project; kConFab/AOCS = The Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer/Australian Ovarian Cancer Study; MCBCS = Mayo Clinic Breast Cancer Study; MCCS = Melbourne Collaborative Cohort Study; N/A = not available; ORIGO = Leiden University Medical Centre Breast Cancer Study; PBCS = Polish Breast Cancer Study; SASBAC = Singapore and Swedish Breast Cancer Study; SBCS = Sheffield Breast Cancer Study; UCIBCS = University of California Irvine Breast Cancer Study.
Grade designations of 1, 2, and 3 represent well differentiated, moderately differentiated, and poorly differentiated, respectively.